Xilonix

BIOLOGICAL3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Advanced Colorectal CancerColorectal Cancer With CachexiaMetastatic Colorectal CancerPyoderma GangrenosumSymptomatic Colorectal Cancer

Phase 2

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

CompletedNCT01965613

Janssen Research & Development, LLCPyoderma Gangrenosum

Start: 2014-01-31End: 2016-12-31Updated: 2025-07-08

Phase 3

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer

TerminatedNCT01767857

Janssen Research & Development, LLCMetastatic Colorectal Cancer

Start: 2013-03-31End: 2017-06-30Updated: 2021-06-29

A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

CompletedNCT02138422

Janssen Research & Development, LLCAdvanced Colorectal Cancer, Colorectal Cancer With Cachexia, Symptomatic Colorectal Cancer

Start: 2014-07-31End: 2015-11-30Target: 276Updated: 2021-03-01

Related Papers

MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (PT026).

Journal of Clinical Oncology2017-05-20

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

2017-01-14125 citations

New Agent in Colorectal Cancer Rapidly Evaluated by Tumor-Related Symptom Control

Oncology Times2016-08-12

Phase III double-blinded, placebo-controlled study of MABp1 for improving survival in metastatic colorectal cancer.

Journal of Clinical Oncology2016-02-012 citations

A phase III study of xilonix in refractory colorectal cancer patients with weight loss.

Journal of Clinical Oncology2015-01-206 citations